
Claims

1. An agent for the treatment and/or prophylaxis of a movement disorder, comprising a thiazole derivative represented by the formula (I)



(I)


wherein R^1 represents aryl, aralkyl, an aromatic heterocyclic group, aromatic heterocycle-alkyl, aliphatic heterocycle-alkyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from the group consisting of halogen; lower alkyl optionally substituted by lower alkoxy or morpholino; lower alkoxy; lower alkanoyl; and vinyl, and R^2 represents pyridyl or tetrahydropyranyl, or a pharmaceutically acceptable salt thereof as an active ingredient.

2. The agent according to claim 1, wherein R^1 is phenyl, pyridyl, pyrimidinyl, 5,6-dihydro-2H-pyridylmethyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from a fluorine atom, a chlorine atom, a bromine atom, methyl, ethyl, methoxy and ethoxy, and R^2 is pyridyl or tetrahydropyranyl.


3. The agent according to claim 1 or 2, wherein R^2 is pyridyl.

4. The agent according to claim 1 or 2, wherein R^2 is tetrahydropyranyl.


5. The agent according to claim 1, wherein the thiazole derivative represented by the formula (I) is a compound represented by any one of the following formulas (IA) - (IAA).




(IA)




(IB)




(IC)




(ID)




(IE)




(IF)




(IG)




(IH)




(II)




(IJ)




(IK)




(IL)




(IM)




(IN)




(IO)




(IP)




(IQ)




(IR)




(IS)




(IT)




(IU)




(IV)




(IW)




(IX)



(IY)



(IZ)



(IAA)

6. The agent according to any one of claims 1 to 5, wherein the movement disorder is extrapyramidal syndrome.

7. The agent according to any one of claims 1 to 5, wherein the movement disorder is bradykinesia, gait disturbance, dystonia, dyskinesia or tardive dyskinesia.


8. The agent according to any one of claims 1 to 5, wherein the movement disorder is a side effect of L-DOPA and/or dopamine agonist therapy.

9. The agent according to claim 8, wherein the side effect is a motor complication.

10. The agent according to claim 9, wherein the motor complication is wearing-off phenomenon.

11. The agent according to claim 9, wherein the motor complication is on-off fluctuation.

12. A pharmaceutical composition comprising (a) a thiazole derivative represented by the formula (I)



(I)

wherein R^1 represents aryl, aralkyl, an aromatic heterocyclic group, aromatic heterocycle-alkyl, aliphatic heterocycle-alkyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from the group consisting of halogen; lower alkyl optionally substituted by lower alkoxy or morpholino; lower alkoxy; lower alkanoyl; and vinyl, and R^2 represents pyridyl or tetrahydropyranyl, or a pharmaceutically acceptable salt thereof, and (b) L-DOPA and/or a dopamine agonist.


13. The pharmaceutical composition according to claim 12, wherein R^1 is phenyl, pyridyl, pyrimidinyl, 5,6-dihydro-2H-pyridylmethyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from a

fluorine atom, a chlorine atom, a bromine atom, methyl, ethyl, methoxy and ethoxy, and R^2 is pyridyl or tetrahydropyranyl.


14. The pharmaceutical composition according to claim 12 or 13, wherein R^2 is pyridyl.

15. The pharmaceutical composition according to claim 12 or 13, wherein R^2 is tetrahydropyranyl.

16. The pharmaceutical composition according to claim 12, wherein the thiazole derivative represented by the formula (I) is a compound represented by any one of the following formulas (IA) - (IAA).



17. An agent for the treatment and/or prophylaxis of Parkinson's disease, comprising (a) a thiazole derivative represented by the formula (I)



(I)


wherein R^1 represents aryl, aralkyl, an aromatic heterocyclic group, aromatic heterocycle-alkyl, aliphatic heterocycle-alkyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from the group consisting of halogen; lower alkyl optionally substituted by lower alkoxy or morpholino; lower alkoxy; lower alkanoyl; and vinyl, and R^2 represents pyridyl or tetrahydropyranyl, or a pharmaceutically acceptable salt thereof, and (b) L-DOPA and/or a dopamine agonist in combination.

18. The agent according to claim 17, wherein R^1 is phenyl, pyridyl, pyrimidinyl, 5,6-dihydro-2H-pyridylmethyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from a fluorine atom, a chlorine atom, a bromine atom, methyl, ethyl, methoxy and ethoxy, and R^2 is pyridyl or tetrahydropyranyl.


19. The agent according to claim 17 or 18, wherein R^2 is pyridyl.

20. The agent according to claim 17 or 18, wherein R^2 is tetrahydropyranyl.


21. The agent according to claim 17, wherein the thiazole derivative represented by the formula (I) is a compound represented by any one of the following formulas (IA) - (IAA).




(IA)




(IB)




(IC)




(ID)




(IE)




(IF)




(IG)




(IH)




(II)




(IJ)




(IK)




(IL)




(IM)




(IN)




(IO)




(IP)




(IQ)




(IR)




(IS)




(IT)




(IU)




(IV)




(IW)




(IX)



(IY)




(IZ)



(IAA)

22. The agent according to any one of claims 17 to 21, for administering (a) and (b) simultaneously or separately at an interval.

23. A kit comprising (a) a first component comprising a thiazole derivative represented by the formula (I)



(I)


wherein R^1 represents aryl, aralkyl, an aromatic heterocyclic group, aromatic heterocycle-alkyl, aliphatic heterocycle-alkyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from the group consisting of halogen; lower alkyl optionally substituted by lower alkoxy or morpholino; lower alkoxy; lower alkanoyl; and vinyl, and R^2 represents pyridyl or tetrahydropyranyl, or a pharmaceutically acceptable salt thereof, and (b) a second component comprising L-DOPA and/or a dopamine agonist.

24. The kit according to claim 23, wherein R^1 is phenyl, pyridyl, pyrimidinyl, 5,6-dihydro-2H-pyridylmethyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from a fluorine atom, a chlorine atom, a bromine atom, methyl, ethyl, methoxy and ethoxy, and R^2 is pyridyl or tetrahydropyranyl.


25. The kit according to claim 23 or 24, wherein R^2 is pyridyl.

26. The kit according to claim 23 or 24, wherein R^2 is tetrahydropyranyl.


27. The kit according to claim 23 wherein the thiazole derivative represented by the formula (I) is a compound represented by any one of the following formulas (IA) - (IAA).




(IA)




(IB)




(IC)




(ID)




(IE)




(IF)




(IG)




(IH)




(II)




(IJ)




(IK)




(IL)




(IM)




(IN)




(IO)




(IP)




(IQ)




(IR)




(IS)




(IT)




(IU)




(IV)




(IW)




(IX)



(IY)




(IZ)



(IAA)

28. A method of treating and/or preventing a movement disorder, comprising administering an effective amount of a thiazole derivative represented by the formula (I)



(I)


wherein R^1 represents aryl, aralkyl, an aromatic heterocyclic group, aromatic heterocycle-alkyl, aliphatic heterocycle-alkyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from the group consisting of halogen; lower alkyl optionally substituted by lower alkoxy or morpholino; lower alkoxy; lower alkanoyl; and vinyl, and R^2 represents pyridyl or tetrahydropyranyl, or a pharmaceutically acceptable salt thereof.

29. The method according to claim 28, wherein R^1 is phenyl, pyridyl, pyrimidinyl, 5,6-dihydro-2H-pyridylmethyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from a fluorine atom, a chlorine atom, a bromine atom, methyl, ethyl, methoxy and ethoxy, and R^2 is pyridyl or tetrahydropyranyl.


30. The method according to claim 28 or 29, wherein R^2 is pyridyl.

31. The method according to claim 28 or 29, wherein R^2 is tetrahydropyranyl.


32. The method according to claim 28, wherein the thiazole derivative represented by the formula (I) is a compound represented by any one of the following formulas (IA) - (IAA).




(IA)




(IB)




(IC)




(ID)




(IE)




(IF)




(IG)




(IH)




(II)




(IJ)




(IK)




(IL)




(IM)




(IN)




(IO)




(IP)




(IQ)




(IR)




(IS)




(IT)




(IU)




(IV)




(IW)




(IX)



(IY)



(IZ)



(IAA)

33. The method according to any one of claims 28 to 32, wherein the movement disorder is extrapyramidal syndrome.

34. The method according to any one of claims 28 to 32, wherein the movement disorder is bradykinesia, gait disturbance, dystonia, dyskinesia or tardive dyskinesia.


35. The method according to any one of claims 28 to 32, wherein the movement disorder is a side effect of L-DOPA and/or dopamine agonist therapy.

36. The method according to claim 35, wherein the side effect is a motor complication.

37. The method according to claim 36, wherein the motor complication is wearing-off phenomenon.

38. The method according to claim 36, wherein the motor complication is on-off fluctuation.

39. A method of treating and/or preventing Parkinson's disease, comprising administering (a) an effective amount of a thiazole derivative represented by the formula (I)



(I)

wherein R^1 represents aryl, aralkyl, an aromatic heterocyclic group, aromatic heterocycle-alkyl, aliphatic heterocycle-alkyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from the group consisting of halogen; lower alkyl optionally substituted by lower alkoxy or morpholino; lower alkoxy; lower alkanoyl; and vinyl, and R^2 represents pyridyl or tetrahydropyranyl, or a pharmaceutically acceptable salt thereof, and (b) an effective amount of L-DOPA and/or a dopamine agonist, simultaneously or separately at an interval.


40. The method according to claim 39, wherein R^1 is phenyl, pyridyl, pyrimidinyl, 5,6-dihydro-2H-pyridylmethyl or tetrahydropyranyloxy, each of which is optionally substituted

by 1 to 3 substituents selected from a fluorine atom, a chlorine atom, a bromine atom, methyl, ethyl, methoxy and ethoxy, and R^2 is pyridyl or tetrahydropyranyl.


41. The method according to claim 39 or 40, wherein R^2 is pyridyl.

42. The method according to claim 39 or 40, wherein R^2 is tetrahydropyranyl.


43. The method according to claim 39, wherein the thiazole derivative represented by the formula (I) is a compound represented by any one of the following formulas (IA) - (IAA).




(IA)




(IB)




(IC)




(ID)




(IE)




(IF)




(IG)




(IH)




(II)




(IJ)




(IK)




(IL)




(IM)




(IN)




(IO)




(IP)




(IQ)




(IR)




(IS)




(IT)




(IU)




(IV)




(IW)




(IX)



(IY)




(IZ)



(IAA)

44. A thiazole derivative represented by the formula (I)



(I)

wherein R^1 represents aryl, aralkyl, an aromatic heterocyclic


group, aromatic heterocycle-alkyl, aliphatic heterocycle-alkyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from the group consisting of halogen; lower alkyl optionally substituted by lower alkoxy or morpholino; lower alkoxy; lower alkanoyl; and vinyl, and R^2 represents pyridyl or tetrahydropyranyl, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prophylaxis of a movement disorder.

45. The thiazole derivative or a pharmaceutically acceptable salt thereof according to claim 44, wherein R^1 is phenyl, pyridyl, pyrimidinyl, 5,6-dihydro-2H-pyridylmethyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from a fluorine atom, a chlorine atom, a bromine atom, methyl, ethyl, methoxy and ethoxy, and R^2 is pyridyl or tetrahydropyranyl.


46. The thiazole derivative or a pharmaceutically acceptable salt thereof according to claim 44 or 45, wherein R^2 is pyridyl.

47. The thiazole derivative or a pharmaceutically acceptable salt thereof according to claim 44 or 45, wherein R^2 is tetrahydropyranyl.


48. The thiazole derivative or a pharmaceutically acceptable salt thereof according to claim 44, wherein the thiazole derivative represented by the formula (I) is a compound represented by any one of the following formulas (IA) - (IAA).




(IA)




(IB)




(IC)




(ID)




(IE)




(IF)




(IG)




(IH)




(II)




(IJ)




(IK)




(IL)




(IM)




(IN)




(IO)




(IP)




(IQ)




(IR)




(IS)




(IT)




(IU)




(IV)




(IW)




(IX)



(IY)



(IZ)



(IAA)

49. The thiazole derivative or a pharmaceutically acceptable salt thereof according to any one of claims 44 to 48, wherein the movement disorder is extrapyramidal syndrome.

50. The thiazole derivative or a pharmaceutically acceptable salt thereof according to any one of claims 44 to 48, wherein the movement disorder is bradykinesia, gait disturbance,

dystonia, dyskinesia or tardive dyskinesia.


51. The thiazole derivative or a pharmaceutically acceptable salt thereof according to any one of claims 44 to 48, wherein the movement disorder is a side effect of L-DOPA and/or dopamine agonist therapy.

52. The thiazole derivative or a pharmaceutically acceptable salt thereof according to claim 51, wherein the side effect is a motor complication.


53. The thiazole derivative or a pharmaceutically acceptable salt thereof according to claim 52, wherein the motor complication is wearing-off phenomenon.

54. The thiazole derivative or a pharmaceutically acceptable salt thereof according to claim 52, wherein the motor complication is on-off fluctuation.

55. A compound represented by any one of the following formulas (IE) - (IAA), or a pharmaceutically acceptable salt thereof.



56. A combination of (a) a thiazole derivative represented by the formula (I)



(I)

wherein R^1 represents aryl, aralkyl, an aromatic heterocyclic group, aromatic heterocycle-alkyl, aliphatic heterocycle-alkyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from the group

consisting of halogen; lower alkyl optionally substituted by lower alkoxy or morpholino; lower alkoxy; lower alkanoyl; and vinyl, and R^2 represents pyridyl or tetrahydropyranyl, or a pharmaceutically acceptable salt thereof, and (b) L-DOPA and/or a dopamine agonist, for use in the treatment and/or prophylaxis of Parkinson's disease.


57. The combination according to claim 56, wherein the use is for administering (a) and (b) simultaneously or separately at an interval.

58. The combination according to claim 56 or 57, wherein R^1 is phenyl, pyridyl, pyrimidinyl, 5,6-dihydro-2H-pyridylmethyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from a fluorine atom, a chlorine atom, a bromine atom, methyl, ethyl, methoxy and ethoxy, and R^2 is pyridyl or tetrahydropyranyl.


59. The combination according to any one of claims 56 to 58, wherein R^2 is pyridyl.

60. The combination according to any one of claims 56 to 58, wherein R^2 is tetrahydropyranyl.


61. The combination according to claim 56 or 57, wherein the thiazole derivative represented by the formula (I) is a compound represented by any one of the following formulas (IA) - (IAA).




(IA)




(IB)




(IC)




(ID)




(IE)




(IF)




(IG)




(IH)




(II)




(IJ)




(IK)




(IL)




(IM)




(IN)




(IO)




(IP)




(IQ)




(IR)




(IS)




(IT)




(IU)




(IV)




(IW)




(IX)



(IY)




(IZ)



(IAA)

62. Use of a thiazole derivative represented by the formula (I)



(I)


wherein R^1 represents aryl, aralkyl, an aromatic heterocyclic group, aromatic heterocycle-alkyl, aliphatic heterocycle-alkyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from the group consisting of halogen; lower alkyl optionally substituted by lower alkoxy or morpholino; lower alkoxy; lower alkanoyl; and vinyl, and R^2 represents pyridyl or tetrahydropyranyl, or a pharmaceutically acceptable salt thereof, for the manufacture of an agent for the treatment and/or prophylaxis of a movement disorder.

63. The use according to claim 62, wherein R^1 is phenyl, pyridyl, pyrimidinyl, 5,6-dihydro-2H-pyridylmethyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from a fluorine atom, a chlorine atom, a bromine atom, methyl, ethyl, methoxy and ethoxy, and R^2 is pyridyl or tetrahydropyranyl.


64. The use according to claim 62 or 63, wherein R^2 is pyridyl.

65. The use according to claim 62 or 63, wherein R^2 is tetrahydropyranyl.


66. The use according to claim 62, wherein the thiazole derivative represented by the formula (I) is a compound represented by any one of the following formulas (IA) - (IAA).




(IA)




(IB)




(IC)




(ID)




(IE)




(IF)




(IG)




(IH)




(II)




(IJ)




(IK)




(IL)




(IM)




(IN)




(IO)




(IP)




(IQ)




(IR)




(IS)




(IT)




(IU)




(IV)




(IW)




(IX)



(IY)



(IZ)



(IAA)

67. The use according to any one of claims 62 to 66, wherein the movement disorder is extrapyramidal syndrome.

68. The use according to any one of claims 62 to 66, wherein the movement disorder is bradykinesia, gait disturbance, dystonia, dyskinesia or tardive dyskinesia.


69. The use according to any one of claims 62 to 66, wherein the movement disorder is a side effect of L-DOPA and/or dopamine agonist therapy.

70. The use according to claim 69, wherein the side effect is a motor complication.

71. The use according to claim 70, wherein the motor complication is wearing-off phenomenon.

72. The use according to claim 70, wherein the motor complication is on-off fluctuation.

73. Use of (a) a thiazole derivative represented by the formula (I)



(I)

wherein R^1 represents aryl, aralkyl, an aromatic heterocyclic group, aromatic heterocycle-alkyl, aliphatic heterocycle-alkyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from the group consisting of halogen; lower alkyl optionally substituted by lower alkoxy or morpholino; lower alkoxy; lower alkanoyl; and vinyl, and R^2 represents pyridyl or tetrahydropyranyl, or a pharmaceutically acceptable salt thereof, and (b) L-DOPA and/or a dopamine agonist for the manufacture of an agent for the treatment and/or prophylaxis of Parkinson's disease.


74. The use according to claim 73, wherein the agent for the treatment and/or prophylaxis of Parkinson's disease is that for administering (a) and (b) simultaneously or separately at an interval.

75. The use according to claim 73 or 74, wherein R^1 is phenyl, pyridyl, pyrimidinyl, 5,6-dihydro-2H-pyridylmethyl or tetrahydropyranyloxy, each of which is optionally substituted by 1 to 3 substituents selected from a fluorine atom, a chlorine atom, a bromine atom, methyl, ethyl, methoxy and ethoxy, and R^2 is pyridyl or tetrahydropyranyl.


76. The use according to any one of claims 73 to 75, wherein R^2 is pyridyl.

77. The use according to any one of claims 73 to 75, wherein R^2 is tetrahydropyranyl.


78. The use according to claim 73 or 74, wherein the thiazole derivative represented by the formula (I) is a compound represented by any one of the following formulas (IA) - (IAA).




(IA)




(IB)




(IC)




(ID)




(IE)




(IF)




(IG)




(IH)




(II)




(IJ)




(IK)




(IL)




(IM)




(IN)




(IO)




(IP)




(IQ)




(IR)




(IS)




(IT)




(IU)




(IV)




(IW)




(IX)



(IY)




(IZ)



(IAA)

Claims

1. The use of a thiazole derivative represented by formula (IC)



(IC)

or a pharmaceutically acceptable salt thereof, in the manufacture of an agent for the treatment and/or prophylaxis of a side effect of L-DOPA and/or dopamine agonist therapy, wherein the dopamine agonist is the one selected from pramipexole, talipexole, ropinirole, cabergoline and pergolide, or a hydrochloride or mesylate thereof.

2. The use according to claim 1, wherein the side effect is a motor complication.

3. The use according to claim 2, wherein the motor complication is wearing-off phenomenon.

4. The use according to claim 2, wherein the motor complication is on-off fluctuation.

5. The use according to claim 2, wherein the motor complication is dyskinesia.

6. The use according to any one of claims 1 to 6, wherein the L-DOPA and/or dopamine agonist therapy is L-DOPA therapy.

7. The use according to claim 1, substantially as herein described with reference to any one of the examples.